095. Levamisole: A Classic Adulterant with a Novel Association

Will R Goodrich¹, Paul Wax², Kim Aldy²,³, Rachel Culbreth⁴, Alex Krotulski⁴, Jeffrey Brent⁵, Sharan Campleman⁶, Barry Logan⁶,⁷, Alexandra Amaducci⁷, Alex F Manini⁸, Shao Li⁹, Alison Meyn⁵, Stephanie Abston², Bryan Judge⁹, Michael Levine¹⁰, Diane P. Calello¹¹, Joshua Shulman¹², Adrienne Hughes¹³, Evan Schwarz¹⁴; On Behalf of the Toxicology Investigators Consortium Fentalog Study Group

¹University of Virginia Health, Charlottesville, VA. ²American College of Medical Toxicology, Phoenix, AZ. ³Baylor University Medical Center, Dallas, TX. ⁴Center for Forensic Science Research and Education at the Fredric Rieders Family Foundation, Willow Grove, PA. ⁵University of Colorado School of Medicine, Aurora, CO. ⁶NMS Labs, Horsham, PA. ⁷Lehigh Valley Health Network/USF Morsani College of Medicine, Allentown, PA. ⁸Icahn School of Medicine at Mount Sinai, New York, NY. ⁹Corewell Health, Michigan State University, Grand Rapids, MI. ¹⁰University of California-Los Angeles, Los Angeles, CA. ¹¹Rutgers New Jersey Medical School, Newark, NJ. ¹²University of Pittsburgh School of Medicine, Pittsburgh, PA. ¹³Oregon Health and Science University, Portland, OR. ¹⁴Washington University School of Medicine, St Louis, MO.

Background: Adulterants are agents added to illicit substances in the drug supply for various reasons—as mimics, synergistic high enhancers, or bulking agents. While classically found in cocaine, levamisole has been detected anecdotally in other substances during the opioid epidemic.

Research Question: What is the prevalence of levamisole detected in the serum of emergency department (ED) patients with confirmed illicit opioid overdose?

Methods: This is a subgroup analysis from the Toxicology Investigators Consortium (ToxIC) Fentalog Study, an ongoing multi-center study across the US. ED patients with suspected opioid overdose were included across eight sites from September 30, 2020 to October 1, 2022. Discarded serum from each patient was analyzed via liquid chromatography quadrupole time-of-flight mass spectroscopy to detect the qualitative prevalence of over 1,000 psychoactive substances and metabolites. Descriptive statistics (R v4.1.2) were calculated for the prevalence of levamisole among confirmed cocaine overdose and confirmed opioid overdose.

Results: From September 30, 2021 to October 1, 2022, 537 samples were collected, of which levamisole was detected in 22.2% (n=119). Additionally, levamisole was present in 60.3% (n=151) of all cocaine-positive patients. The majority of levamisole was discovered in the northeast region of the US (62.2%) (p=0.01). Levamisole was also present in patients without stimulants; it was detected in 5.8% (N=103) of patients with fentanyl without stimulants. Levamisole was identified in the majority of patients (54.5%) with fentanyl, non-fentanyl opioids, and stimulants.
Conclusion: In this large multi-center subgroup analysis of ED patients with confirmed opioid overdose, levamisole prevalence was higher than expected. Levamisole may now be more commonly found in opioids, even in the absence of stimulants.